The First in China: AmcellGene Achieves Breakthrough in Business Development

Recently, Tianjin Amcellgene Engineering Co., Ltd. announced a collaboration with Hong Kong Regen Medtech Limited, granting the latter exclusive rights for the Hong Kong region to its core pipeline product—mesenchymal stem cell (umbilical cord) injection for the treatment of acute-on-chronic liver failure. The transaction adopts a model of "upfront payment + milestone payments + sales royalty," marking the first time a domestic stem cell drug company has achieved a breakthrough in business development beyond the customs territory. This signifies that China's innovative achievements in cell therapy have entered a new stage of international commercialization.

Established in TEDA in 2004, Tianjin AmCell Gene Engineering Co., Ltd. is the legal entity of the National Engineering Center of Cell Products. The company has built the world’s first mesenchymal stem cell bank and applied for China’s first umbilical cord mesenchymal stem cell therapeutic drug. To date, it has advanced six stem cell indications into clinical trials.